Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

TPG Will Acquire Par Pharmaceutical

by Ann M. Thayer
July 23, 2012 | A version of this story appeared in Volume 90, Issue 30

Private investment firm TPG has agreed to acquire Par Pharmaceutical, based in Woodcliff Lake, N.J., in a deal worth $1.9 billion. Under the agreement, Par shareholders will receive $50 in cash for each share, a 37% premium over the share price before the deal was announced. However, Par can look for superior offers through Aug. 24, and its board is actively soliciting them. Par develops generic drugs under the Par name and niche proprietary drugs under the Strativa name.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.